- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Upadacitinib increases risk of herpes zoster, serious infections and skin cancer in RA patients: BMJ
In a recent study examining the safety of upadacitinib in rheumatoid arthritis (RA) patients, researchers have reported an increased risk of serious adverse events (AEs) in individuals aged 50 years and above, with cardiovascular (CV) risk factors. The findings were published in the Annals of the Rheumatic Diseases.
The research analyzed data from six phase III clinical trials involving a total of 3209 patients receiving upadacitinib 15 mg once daily, 579 patients receiving adalimumab (a tumor necrosis factor inhibitor) with concomitant methotrexate (MTX), and 314 patients on MTX monotherapy. Approximately 54% of the patients were included in the higher-risk population, as they were aged 50 years and above and had at least one CV risk factor.
The findings showed that major adverse cardiovascular events (MACE), malignancies (excluding non-melanoma skin cancer), and venous thromboembolism (VTE) were more frequent in the higher-risk groups compared to the overall population. However, the incidence rates of these adverse events were similar between patients treated with upadacitinib and those treated with adalimumab.
Moreover, the study identified higher rates of serious infections in upadacitinib-treated patients within the higher-risk population. Additionally, upadacitinib showed increased rates of non-melanoma skin cancer (NMSC) and herpes zoster (HZ) across all populations compared to the comparators.
The study's post hoc analysis raises concerns about the safety of upadacitinib in RA patients aged 50 years and older with cardiovascular risk factors. While the risk of MACE, malignancies, and VTE was found to be comparable between upadacitinib and adalimumab, the higher rates of serious infections, NMSC, and HZ with upadacitinib demand careful consideration.
Rheumatoid arthritis is a chronic inflammatory disease that affects millions of people worldwide. The advent of novel therapies has improved patient outcomes significantly. However, the safety profiles of these drugs need continuous evaluation to ensure the well-being of patients.
The authors of the study emphasize the importance of individualized treatment decisions, taking into account the patient's age, CV risk factors, and overall health status. Additionally, close monitoring for potential adverse events is crucial during the course of therapy with upadacitinib or other targeted treatments.
Source:
Fleischmann, R., Curtis, J. R., Charles-Schoeman, C., Mysler, E., Yamaoka, K., Richez, C., Palac, H., Dilley, D., Liu, J., Strengholt, S., & Burmester, G. (2023). Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. In Annals of the Rheumatic Diseases (p. ard-2023-223916). BMJ. https://doi.org/10.1136/ard-2023-223916
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751